

Peter J Hosein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1695018/publications.pdf>

Version: 2024-02-01

46
papers

2,191
citations

430874

18
h-index

276875

41
g-index

46
all docs

46
docs citations

46
times ranked

3698
citing authors

#	ARTICLE	IF	CITATIONS
1	The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens. <i>Pharmacogenomics Journal</i> , 2021, 21, 308-317.	2.0	4
2	Intestinal Autotransplantation and In-Situ Resection of Recurrent Pancreatic Head Intraductal Tubulopapillary Neoplasm with Portal Cavernoma: A Case Report. <i>Transplantation Proceedings</i> , 2021, 53, 2598-2601.	0.6	0
3	Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3603-3614.	4.1	121
4	DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 1133-1139.	1.4	20
5	Does Neoadjuvant Chemotherapy Change the Role of Regional Lymphadenectomy in Pancreatic Cancer Survival?. <i>Pancreas</i> , 2019, 48, 823-831.	1.1	9
6	The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 135-139.	1.4	11
7	Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E19-E22.	1.4	1
8	Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 9-15.	3.7	12
9	Neoadjuvant nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. <i>Anticancer Research</i> , 2018, 38, 4035-4039.	1.1	14
10	Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection. , 2018, 6, 66.		21
11	Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. <i>Journal of Surgical Research</i> , 2017, 214, 1-8.	1.6	17
12	Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 342-348.	0.5	100
13	Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. <i>BMC Cancer</i> , 2017, 17, 602.	2.6	17
14	Colorectal Tumors From Different Racial and Ethnic Minorities Have Similar Rates of Mismatch Repair Deficiency. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1163-1171.	4.4	22
15	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 801-810.	10.7	719
16	Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 232-240.	0.5	4
17	Cancer stem cell marker expression alone and in combination with microvascular invasion predicts poor prognosis in patients undergoing transplantation for hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2016, 212, 238-245.	1.8	18
18	Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. <i>Hpb</i> , 2016, 18, 29-34.	0.3	83

#	ARTICLE	IF	CITATIONS
19	Updated survival analysis of two sequential prospective trials of Râ€MACLOâ€VAM followed by maintenance for newly diagnosed mantle cell lymphoma. American Journal of Hematology, 2015, 90, E111-6.	4.1	6
20	Phase II study of⁹⁰Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leukemia and Lymphoma, 2015, 56, 1750-1755.	1.3	26
21	Percutaneous Approach to Irreversible Electroporation of the Pancreas: Miami Protocol. Techniques in Vascular and Interventional Radiology, 2015, 18, 153-158.	1.0	11
22	Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology, 2015, 15, 667-673.	1.1	73
23	A cohort study evaluating the role of surgery for lung metastases from colorectal cancer. Anticancer Research, 2015, 35, 3431-5.	1.1	3
24	A multicentre study of primary breast diffuse large <scp>B</scp>â€cell lymphoma in the rituximab era. British Journal of Haematology, 2014, 165, 358-363.	2.5	91
25	<scp>LMO</scp>2 and <scp>BCL</scp>6 are associated with improved survival in primary central nervous system lymphoma. British Journal of Haematology, 2014, 165, 640-648.	2.5	26
26	Percutaneous Irreversible Electroporation for the Treatment of Colorectal Cancer Liver Metastases with a Proposal for a New Response Evaluation System. Journal of Vascular and Interventional Radiology, 2014, 25, 1233-1239.e2.	0.5	51
27	Phase II study of 90y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma. Blood, 2014, 124, 1762-1762.	1.4	0
28	Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Research, 2014, 34, 301-6.	1.1	11
29	A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 151-156.	1.3	94
30	A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leukemia and Lymphoma, 2012, 53, 1299-1305.	1.3	12
31	Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. Journal of Vascular and Interventional Radiology, 2012, 23, 1613-1621.	0.5	205
32	A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer, 2012, 12, 199.	2.6	198
33	Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Medical Oncology, 2012, 29, 1707-1710.	2.5	10
34	Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab. International Journal of Hematology, 2012, 96, 274-278.	1.6	13
35	A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and nonâ€Hodgkin's lymphoma. American Journal of Hematology, 2012, 87, 111-114.	4.1	26
36	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. Blood, 2012, 120, 1618-1618.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 1622-1622.	1.4	0
38	Radiopharmaceuticals: When and How to Use Them to Treat Metastatic Bone Pain. <i>The Journal of Supportive Oncology</i> , 2011, 9, 197-205.	2.3	25
39	Utility of positron emission tomography scans in mantle cell lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 841-845.	4.1	55
40	A Multicenter Study Evaluating the Efficacy and Safety of Bendamustine in the Treatment of Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 4940-4940.	1.4	0
41	Accuracy of Endobronchial Ultrasound-Directed Transbronchial Needle Aspiration (EBUS-TBNA) for Diagnosis of Mediastinal Lymphadenopathy in Patients With Suspected Malignancy. <i>Chest</i> , 2010, 138, 427A.	0.8	1
42	High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 406-414.	1.3	16
43	Severe colitis associated with docetaxel use: A report of four cases. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 390.	2.0	22
44	The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma. <i>European Journal of Clinical & Medical Oncology</i> , 2010, 2, 131-138.	0.0	4
45	Role of Combined-Modality Therapy in the Management of Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 369-375.	2.3	15
46	High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T. <i>Blood</i> , 2008, 112, 3597-3597.	1.4	2